GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thalys Medical Technology Group Corp (SHSE:603716) » Definitions » Intrinsic Value: Projected FCF

Thalys Medical Technology Group (SHSE:603716) Intrinsic Value: Projected FCF : ¥1.88 (As of Jun. 05, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Thalys Medical Technology Group Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-05), Thalys Medical Technology Group's Intrinsic Value: Projected FCF is ¥1.88. The stock price of Thalys Medical Technology Group is ¥12.24. Therefore, Thalys Medical Technology Group's Price-to-Intrinsic-Value-Projected-FCF of today is 6.5.

The historical rank and industry rank for Thalys Medical Technology Group's Intrinsic Value: Projected FCF or its related term are showing as below:

SHSE:603716' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.52   Med: 7.11   Max: 15.55
Current: 6.51

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Thalys Medical Technology Group was 15.55. The lowest was 2.52. And the median was 7.11.

SHSE:603716's Price-to-Projected-FCF is ranked worse than
95.1% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.41 vs SHSE:603716: 6.51

Thalys Medical Technology Group Intrinsic Value: Projected FCF Historical Data

The historical data trend for Thalys Medical Technology Group's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thalys Medical Technology Group Intrinsic Value: Projected FCF Chart

Thalys Medical Technology Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 -2.84 -2.84 0.77 2.87

Thalys Medical Technology Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 0.95 2.01 2.87 1.88

Competitive Comparison of Thalys Medical Technology Group's Intrinsic Value: Projected FCF

For the Diagnostics & Research subindustry, Thalys Medical Technology Group's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thalys Medical Technology Group's Price-to-Projected-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thalys Medical Technology Group's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Thalys Medical Technology Group's Price-to-Projected-FCF falls into.


;
;

Thalys Medical Technology Group Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Thalys Medical Technology Group's Free Cash Flow(6 year avg) = ¥-36.95.

Thalys Medical Technology Group's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar25)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-36.95088+920.025*0.8)/204.585
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thalys Medical Technology Group  (SHSE:603716) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Thalys Medical Technology Group's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=12.24/1.8781173136823
=6.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thalys Medical Technology Group Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Thalys Medical Technology Group's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Thalys Medical Technology Group Business Description

Traded in Other Exchanges
N/A
Address
1310 Jinshan Avenue, Dongxihu District, Hubei Province, Wuhan, CHN, 430040
Thalys Medical Technology Group Corp is engaged in intensive sales business, pure sales, and research and development, production and sales of independent in vitro diagnostic products.
Executives
Wang Jun Ming senior management
Wang Zheng senior management
Wang Wen Bin senior management
Liu Wen Hao Director
Huang Yong Xi senior management
Lei Xian Kun Director
Fan Li Director
Liu Yuan senior management
Wan Li Bo senior management
Wen Wei Director
Chou Jian senior management
Song Yu Director

Thalys Medical Technology Group Headlines

No Headlines